AMGN Overview
Upcoming Projects (AMGN)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (AMGN)
-
Understanding the latest R&D advances and clinical development trends in obesity management
Tickers: RHHBY, AMGN, AZN
Executed On: Feb 12, 2024 at 03:00 PM EST -
Discussing Amgen's sotorasib, in KRAS G12C-mutated mCRC and the results from the P3 CodeBreak 300 study presented at ESMO 2023
Ticker: AMGN
Executed On: Nov 15, 2023 at 09:00 AM EST -
Discussing the MARIPOSA & PAPILLON data for J&J's RYBREVANT (amivantamab-vmjw) in EGFR-mutated lung cancer presented at ESMO 2023
Tickers: JNJ, AMGN
Executed On: Nov 06, 2023 at 01:00 PM EST -
Discussing the data from the 2023 Triple Meeting on Amgen's AMG 193 in solid tumors with MTAP deficiency with the Lead Presenter
Ticker: AMGN
Executed On: Oct 30, 2023 at 10:30 AM EDT -
Discussing the potential of Amgen's KRAS-G12C- inhibitor, sotorasib, in KRAS G12C-mutated mCRC and the results from the CodeBreak 300 phase III study presented at the 2023 ESMO conference.
Ticker: AMGN
Executed On: Oct 27, 2023 at 01:05 PM EDT -
Discussing Novel Therapies in Dermatology with a focus on TYK2 in Psoriasis, IL-13 & OX-40(L) in Atopic Dermatitis and IL-17 in Hidradenitis Suppurativa
Tickers: REGN, BMY, AMGN
Executed On: Oct 18, 2023 at 12:30 PM EDT -
Digging into the Phase 2 data on Horizon's dazodalibep for Sjögren’s Syndrome
Tickers: HZNP, AMGN
Executed On: Jan 27, 2023 at 05:00 PM EST -
A Second View: Discussing Amgen's OCEAN(a) study and the potential of olpasiran in treating patients with elevated Lipoprotein(a) and evidence of atherosclerotic cardiovascular disease (ASCVD)
Ticker: AMGN
Executed On: Aug 01, 2022 at 02:30 PM EDT -
A dive into the Amgen's OCEAN(a) study and the potential of olpasiran in treating patients with elevated Lipoprotein(a) and evidence of atherosclerotic cardiovascular disease (ASCVD)
Ticker: AMGN
Executed On: Jul 11, 2022 at 04:15 PM EDT
Expired Projects (AMGN)
-
Discussing the recent ESMO data on Amgen's KRAS-G12C- inhibitor, sotorasi, from the CodeBreak 300 Phase 3 trial in mCRC
Ticker: AMGN
Execute By: Nov 02, 2023 -
Discussing the full ASCO 2019 update for AMG 510 after Amgen's Analyst call on Monday
Ticker: AMGN
Execute By: Jun 07, 2019 -
A Second Opinion: Preparing for Eptinezumab's data in Chronic Migraine after study changes and additional data from Erenumab
Tickers: ALDR, AMGN, TEVA, NVS
Execute By: May 17, 2017 -
Evaluating the Chances of Approval and Market Potential for Radius Health's (RDUS) Abaloparatide-SC for Postmenopausal Women with Osteoporosis
Tickers: RDUS, AMGN, LLY
Execute By: May 09, 2017
Upcoming & Overdue Catalysts (AMGN)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (AMGN)
-
New Phase 1 Clinical Data Evaluating Amgen's (AMGN) AMG 510 In Patients With Solid Tumors Presented At ESMO 2019
Ticker: AMGN
Occurred on: Sep 27, 2019 -
Top line data from PROMISE 2, a Phase 3 study of Eptinezumab in 1,500 Chronic Migraine patients
Tickers: ALDR, TEVA, AMGN
Occurred on: Feb 26, 2018 -
The FDA has set a Biosimilar User Fee Act target action date of Sept 14 2017 for ABP 215
Ticker: AMGN
Occurred on: Sep 14, 2017 -
Amgen (AMGN) submits Biologics License Application (BLA) to FDA for ABP 980, a treatment for breast cancer
Ticker: AMGN
Occurred on: Jul 31, 2017 -
Amgen (AMGN) set for July 19th PDUFA decision for EVENITY, a treatment for osteoporosis in postmenopausal women
Ticker: AMGN
Occurred on: Jul 16, 2017 -
The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of July 19, 2017, for romosozumab
Ticker: AMGN
Occurred on: Jul 16, 2017 -
Amgen (AMGN) earns unanimous approval from FDA advisory committee for ABP-215, with PDUFA date set for September
Ticker: AMGN
Occurred on: Jul 13, 2017 -
Amgen's (AMGN) BLINCYTO earns FDA approval for relasped or refractory B-cell acute lymphoblastic leukemia
Ticker: AMGN
Occurred on: Jul 13, 2017 -
MRK's CETP CV outcomes for hypercholesterolemia expected in Q1 2017
Tickers: MRK, AMGN, ESPR
Occurred on: Jun 27, 2017 -
PDUFA Date of October 9th for Mylan's (MYL) Biologics License Application for Biosimilar to Amgen's (AMGN) Neulasta
Tickers: AMGN, MYL
Occurred on: Jun 12, 2017 -
Sanofi (SNY) and Regeneron (REGN) Announce U.S Lawsuit Against Amgen (AMGN) Over Patent for Asthma Drug
Tickers: AMGN, REGN, SNY
Occurred on: Mar 21, 2017 -
Amgen (AMGN) Phase 3 ENDEAVOR Data Comparing Kyprolis to Takeada's (TKPYY) Velcade in Relapsed/Refractory Multiple Myeloma
Tickers: AMGN, TKPYY
Occurred on: Feb 28, 2017 -
Data from Amgen's (AMGN) Phase 3 FOURIER Coronary Imaging Study Evaluating Repatha in High Cholesterol Patients Expected Q1 2017
Ticker: AMGN
Occurred on: Feb 02, 2017 -
Delaware District Court Denies Sanofi (SNY) and Regeneron's (REGN) Motion to Stay the Injunction in PCSK9 Patent Dispute with Amgen (AMGN)
Tickers: REGN, AMGN, SNY
Occurred on: Jan 09, 2017 -
Amgen (AMGN) and Astellas Pharma (ALPMY) File Marketing Application in Japan for Romosozumab in Osteoporosis Patients at High Risk of Fracture
Tickers: AMGN, ALPMY
Occurred on: Dec 19, 2016 -
European Commission Approves Parsabiv (etelcalcetide) For The Treatment Of Secondary Hyperparathyroidism In Adults On Hemodialysis
Ticker: AMGN
Occurred on: Nov 11, 2016 -
PDUFA of Enbrel in Pediatric patients with moderate-severe psoriasis set for Nov 5 2016
Ticker: AMGN
Occurred on: Nov 04, 2016 -
Amgen (AMGN) Announces Top-Line Results From Phase 3 KYPROLIS (Carfilzomib) CLARION Study In Newly Diagnosed Multiple Myeloma Patients
Ticker: AMGN
Occurred on: Sep 27, 2016 -
Amgen Announces FDA Advisory Committee Meeting To Review ABP 501, A Biosimilar Candidate To Adalimumab
Ticker: AMGN
Occurred on: Sep 23, 2016 -
Amgen's (AMGN) AMJEVITA Approved by FDA for Seven Inflammatory Diseases
Ticker: AMGN
Occurred on: Sep 23, 2016 -
Amgen (AMGN) and UCB Announce Phase III FRAME Results Evaluating Romosozumab in Postmenopausal Women with Osteoporosis
Ticker: AMGN
Occurred on: Sep 18, 2016 -
European Ad Comm Recommends for Approval Amgen's (AMGN) Parsabiv in Treatment of Secondary Hyperthyroidism
Ticker: AMGN
Occurred on: Sep 16, 2016 -
Development of Omecamtiv Mecarbil Questionable to Continue to Phase 3 - Decision Expected This Year
Tickers: CYTK, AMGN
Occurred on: Sep 01, 2016 -
Amgen Announces Positive Top-Line Results From Phase 3 Study Of Prolia (Denosumab) In Patients Receiving Glucocorticoid Therapy
Ticker: AMGN
Occurred on: Aug 29, 2016 -
New Repatha (evolocumab) Analyses Show Efficacy And Safety Across Risk Groups In Results Presented At ESC Congress 2016
Ticker: AMGN
Occurred on: Aug 28, 2016 -
New Data Add To Understanding Of Repatha (Evolocumab) In Multiple Patient Populations
Ticker: AMGN
Occurred on: Aug 22, 2016 -
AbbVie files patent lawsuit seeking to stop Amgen’s copy of Humira
Tickers: ABBV, AMGN
Occurred on: Aug 05, 2016 -
Amgen And UCB Submit Biologics License Application For Romosozumab To The FDA
Ticker: AMGN
Occurred on: Jul 22, 2016 -
Ad Comm review on July 12 for Amgen's Humira biosimilar ABP 501
Ticker: AMGN
Occurred on: Jul 13, 2016 -
Amgen To Discuss Data Supporting Biologics License Application For ABP 501, A Biosimilar Candidate To Adalimumab
Ticker: AMGN
Occurred on: Jul 12, 2016 -
Ad Comm review July 13 for Novartis Enbrel biosimilar GP2015
Tickers: NVS, AMGN
Occurred on: Jul 12, 2016 -
FDA Approves First And Only Single Monthly Injection For A PCSK9 Inhibitor
Ticker: AMGN
Occurred on: Jul 11, 2016 -
BLINCYTO (Blinatumomab) Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia
Ticker: AMGN
Occurred on: Jun 10, 2016 -
Amgen Receives Positive CHMP Opinion To Extend Indication Of Kyprolis (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma
Ticker: AMGN
Occurred on: May 27, 2016 -
Amgen And UCB Announce Positive Top-Line Results From The Phase 3 Study Of Romosozumab In Postmenopausal Women With Osteoporosis
Ticker: AMGN
Occurred on: Feb 21, 2016 -
FDA Approves New Kyprolis (Carfilzomib) Combination Therapy For The Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma
Ticker: AMGN
Occurred on: Jan 21, 2016 -
Amgen's Repatha (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol
Ticker: AMGN
Occurred on: Jan 21, 2016
Strategic Initiatives (AMGN)
-
Amgen (AMGN) completes $1.9B acquisition of Five Prime Therapeutics (FPRX)
Tickers: AMGN, FPRX
Announcement Date: Apr 16, 2021 -
Amgen (AMGN) Agrees to Strategic Collaboration with Immatics Biotechnologies GmbH to Develop T-Cell Immunotherapies for a Range of Cancers
Tickers: AMGN, Immatics Biotechnologies GmbH
Announcement Date: Jan 09, 2017 -
Davita (DVA) Signs 6-Year Agreement to Supply Amgen (AMGN) with Epogen and Aranesp in U.S and Puerto Rico
Tickers: AMGN, DVA
Announcement Date: Jan 09, 2017 -
Amgen (AMGN) and Janssen (JNJ) Announce Collaboration Deal to Evaluate Kyprolis and Darzalex in Multiple Myeloma
Tickers: AMGN, JNJ
Announcement Date: Nov 10, 2016 -
Dr. Reddy (RDY) Expands Collaboration with Amgen (AMGN), Agrees to Market and Distribute XGEVA, Vectibix, and Prolia in India
Tickers: RDY, AMGN
Announcement Date: Sep 16, 2016 -
Amgen And Daiichi Sankyo Announce Agreement To Commercialize Biosimilars In Japan
Tickers: AMGN, D4S.F
Announcement Date: Jul 13, 2016 -
Unilife and Amgen Enter Strategic Collaboration for Injectable Drug Delivery Systems
Tickers: AMGN, UNIS
Announcement Date: Feb 22, 2016
